All the news Showing 10 of 33 articles from: EASL 2015Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Deciding when and how to treat HCV Another study confirms detrimental effects of delaying hepatitis C treatment Liz Highleyman / 05 May 2015 Deferring antiviral therapy for hepatitis C until a person progresses to advanced liver disease has clear drawbacks including lower treatment effectiveness and an increased risk of clinical events and death, according to ... Cirrhosis Sofosbuvir, daclatasvir and ribavirin cures hepatitis C for most people with advanced cirrhosis or liver transplants Liz Highleyman / 29 April 2015 An interferon-free regimen of sofosbuvir, daclatasvir and ribavirin for 12 weeks produced sustained response rates of 83% for people with hepatitis C virus (HCV) who had advanced liver cirrhosis and 94% for ... Genotype 3 Sofosbuvir plus pegylated interferon/ribavirin is highly effective for people with hard-to-treat genotype 3 hepatitis C Liz Highleyman / 29 April 2015 A throwback regimen of sofosbuvir (Sovaldi), ribavirin and pegylated interferon taken for 12 weeks cured 93% of people with hepatitis C virus (HCV) genotype 3 – substantially more than sofosbuvir plus ribavirin alone ... Treatment in kidney dialysis Merck's grazoprevir/elbasvir combo cures 99% of hepatitis C in chronic kidney disease Keith Alcorn / 29 April 2015 The once-daily combination of grazoprevir and elbasvir cured hepatitis C in 99% of people with advanced chronic kidney disease, researchers reported at the International Liver Congress last week in Vienna, Austria. The findings ... Treatment guidelines New EASL guidelines prioritise interferon-free hepatitis C treatment Liz Highleyman / 28 April 2015 The European Association for the Study of the Liver (EASL) released its latest hepatitis C treatment guidelines at the 50th International Liver Congress which took place last week in Vienna, Austria. The ... HBV vaccination Expanded vaccination and treatment could help eliminate hepatitis B worldwide Liz Highleyman / 28 April 2015 While universal infant hepatitis B virus (HBV) vaccination has already led to major advances in reducing new infections in some settings, further expansion of prevention and treatment are needed to significantly reduce HBV ... Prognosis and disease progression Alcohol misuse the strongest predictor of severe liver damage and death in French people with hepatitis C Keith Alcorn / 28 April 2015 People with hepatitis C have a much greater risk of liver-related hospitalisation or death if they have an alcohol use disorder or another serious co-morbidity such as HIV infection, chronic kidney disease ... Treatment for previous non-responders & relapsers Grazoprevir/elbasvir highly effective in treatment-experienced and HIV-coinfected hepatitis C patients Keith Alcorn / 25 April 2015 The combination of grazoprevir and elbasvir without ribavirin is highly effective in curing hepatitis C infection in 12 weeks in some groups of treatment-experienced patients and in people with HIV co-infection, and a ... Testing for liver fibrosis & cirrhosis Advanced liver damage is common in people with undiagnosed hepatitis C in US survey Keith Alcorn / 25 April 2015 Around one in five of people with hepatitis C in the United States who do not know of their infection may already have advanced liver damage and be in urgent need of ... Interferon-free regimens Grazoprevir / elbasvir highly effective in previously untreated hepatitis C Keith Alcorn / 24 April 2015 A 12-week course of the combination of grazoprevir and elbasvir cured 95% of previously untreated people with gentoypes 1, 4 or 6 hepatitis C infection, according to results of the C-EDGE trial, ... ← Prev1234Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive